Aduro BioTech Inc (NASDAQ:ADRO) insider Stephen T. Isaacs sold 7,949 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $7.95, for a total transaction of $63,194.55. Following the completion of the transaction, the insider now owns 213,695 shares of the company’s stock, valued at $1,698,875.25. The sale was disclosed in a filing with the SEC, which is available at this link.
Aduro BioTech Inc (NASDAQ ADRO) opened at $6.30 on Thursday. Aduro BioTech Inc has a fifty-two week low of $6.01 and a fifty-two week high of $14.05. The firm has a market cap of $517.93, a price-to-earnings ratio of -4.63 and a beta of 3.52.
Aduro BioTech (NASDAQ:ADRO) last posted its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.03). The firm had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $4.04 million. Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The firm’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.54) earnings per share. analysts anticipate that Aduro BioTech Inc will post -1.28 EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the company. Harvard Management Co. Inc. bought a new stake in shares of Aduro BioTech during the third quarter worth $69,418,000. Vanguard Group Inc. lifted its position in shares of Aduro BioTech by 5.4% during the second quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock worth $28,637,000 after purchasing an additional 129,079 shares during the last quarter. State Street Corp lifted its position in shares of Aduro BioTech by 8.3% during the second quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock worth $7,808,000 after purchasing an additional 52,597 shares during the last quarter. Baillie Gifford & Co. lifted its position in shares of Aduro BioTech by 30.8% during the third quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock worth $5,891,000 after purchasing an additional 130,390 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Aduro BioTech by 15.1% during the second quarter. Northern Trust Corp now owns 453,115 shares of the biotechnology company’s stock worth $5,166,000 after purchasing an additional 59,490 shares during the last quarter. Institutional investors and hedge funds own 45.19% of the company’s stock.
Several analysts recently commented on ADRO shares. HC Wainwright set a $18.00 price objective on shares of Aduro BioTech and gave the company a “buy” rating in a research report on Wednesday, November 1st. Oppenheimer assumed coverage on shares of Aduro BioTech in a research note on Monday, October 30th. They issued a “buy” rating and a $15.00 price objective on the stock. Canaccord Genuity set a $30.00 target price on shares of Aduro BioTech and gave the stock a “buy” rating in a research note on Thursday, December 14th. Finally, BidaskClub upgraded shares of Aduro BioTech from a “strong sell” rating to a “sell” rating in a research note on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. Aduro BioTech presently has a consensus rating of “Buy” and a consensus target price of $17.71.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Aduro BioTech Inc (ADRO) Insider Sells 7,949 Shares of Stock” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/01/insider-selling-aduro-biotech-inc-adro-insider-sells-7949-shares-of-stock.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.